State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET
Tóm tắt
Từ khóa
Tài liệu tham khảo
Juweid, 2006, Positron-emission tomography and assessment of cancer therapy, N Engl J Med, 354, 496, 10.1056/NEJMra050276
Allen-Auerbach, 2009, Measuring response with FDG-PET: methodological aspects, Oncologist, 14, 369, 10.1634/theoncologist.2008-0119
Herrmann, 2011, (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go, Q J Nucl Med Mol Imaging, 55, 620
Hutchings, 2009, PET/CT for therapy response assessment in lymphoma, J Nucl Med, 50, 21S, 10.2967/jnumed.108.057190
Bai, 2013, Tumor quantification in clinical positron emission tomography, Theranostics, 3, 787, 10.7150/thno.5629
Tomasi, 2012, Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future, Mol Imaging Biol, 14, 131, 10.1007/s11307-011-0514-2
Boellaard, 2010, FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, Eur J Nucl Med Mol Imaging, 37, 181, 10.1007/s00259-009-1297-4
Boellaard, 2011, Need for standardization of 18F-FDG PET/CT for treatment response assessments, J Nucl Med, 52, 93S, 10.2967/jnumed.110.085662
Kraeber-Bodéré, 2014, Challenges in nuclear medicine: innovative theranostic tools for personalized medicine, Front Med, 1, 16, 10.3389/fmed.2014.00016
Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800
Wahl, 2009, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, 50, 122S, 10.2967/jnumed.108.057307
Beyer, 2011, Variations in clinical PET/CT operations: results of an international survey of active PET/CT users, J Nucl Med, 52, 303, 10.2967/jnumed.110.079624
Kim, 1994, Standardized uptake values of FDG: body surface area correction is preferable to body weight correction, J Nucl Med, 35, 164
Tahari, 2014, Optimum lean body formulation for correction of standardized uptake value in PET imaging, J Nucl Med, 55, 1481, 10.2967/jnumed.113.136986
Boellaard, 2004, Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study, J Nucl Med, 45, 1519
Thie, 2004, Understanding the standardized uptake value, its methods, and implications for usage, J Nucl Med, 45, 1431
Krak, 2005, Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial, Eur J Nucl Med Mol Imaging, 32, 294, 10.1007/s00259-005-1926-5
Kinahan, 2010, Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy, Semin Ultrasound CT MR, 31, 496, 10.1053/j.sult.2010.10.001
Adams, 2010, A systematic review of the factors affecting accuracy of SUV measurements, AJR Am J Roentgenol, 195, 310, 10.2214/AJR.10.4923
Soret, 2007, Partial-volume effect in PET tumor imaging, J Nucl Med, 48, 932, 10.2967/jnumed.106.035774
Erlandsson, 2012, A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology, Phys Med Biol, 57, R119, 10.1088/0031-9155/57/21/R119
Nahmias, 2008, Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors, J Nucl Med, 49, 1804, 10.2967/jnumed.108.054239
de Langen, 2012, Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis, J Nucl Med, 53, 701, 10.2967/jnumed.111.095299
Lodge, 2012, Noise considerations for PET quantification using maximum and peak standardized uptake value, J Nucl Med, 53, 1041, 10.2967/jnumed.111.101733
Bal, 2014, Improving PET spatial resolution and detectability for prostate cancer imaging, Phys Med Biol, 59, 4411, 10.1088/0031-9155/59/15/4411
Vanderhoek, 2012, Impact of the definition of peak standardized uptake value on quantification of treatment response, J Nucl Med, 53, 4, 10.2967/jnumed.111.093443
Boktor, 2013, Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET, J Nucl Med, 54, 677, 10.2967/jnumed.112.108530
Hasenclever, 2014, qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma, Eur J Nucl Med Mol Imaging, 41, 1301, 10.1007/s00259-014-2715-9
Larson, 1999, Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis, Clin Positron Imaging, 2, 159, 10.1016/S1095-0397(99)00016-3
Zaidi, 2010, PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques, Eur J Nucl Med Mol Imaging, 37, 2165, 10.1007/s00259-010-1423-3
Schaefer, 2008, A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data, Eur J Nucl Med Mol Imaging, 35, 1989, 10.1007/s00259-008-0875-1
Vauclin, 2009, Development of a generic thresholding algorithm for the delineation of 18FDG-PET-positive tissue: application to the comparison of three thresholding models, Phys Med Biol, 54, 6901, 10.1088/0031-9155/54/22/010
Reutter, 1997, Automated 3-d segmentation of respiratory-gated pet transmission images, IEEE Trans Nucl Sci, 44, 2473, 10.1109/23.656454
Riddell, 1999, The watershed algorithm: a method to segment noisy pet transmission images, IEEE Trans Nucl Sci, 46, 713, 10.1109/23.775604
Geets, 2007, A gradient-based method for segmenting FDG-PET images: methodology and validation, Eur J Nucl Med Mol Imaging, 34, 1427, 10.1007/s00259-006-0363-4
Belhassen, 2010, A novel fuzzy C-means algorithm for unsupervised heterogeneous tumor quantification in PET, Med Phys, 37, 1309, 10.1118/1.3301610
Hatt, 2009, A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET, IEEE Trans Med Imaging, 28, 881, 10.1109/TMI.2008.2012036
Tylski, 2010, Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET, J Nucl Med, 51, 268, 10.2967/jnumed.109.066241
Cheebsumon, 2011, Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology, Eur J Nucl Med Mol Imaging, 38, 2136, 10.1007/s00259-011-1899-5
Hatt, 2011, PET functional volume delineation: a robustness and repeatability study, Eur J Nucl Med Mol Imaging, 38, 663, 10.1007/s00259-010-1688-6
Prieto, 2012, Twelve automated thresholding methods for segmentation of PET images: a phantom study, Phys Med Biol, 57, 3963, 10.1088/0031-9155/57/12/3963
Frings, 2010, Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer, J Nucl Med, 51, 1870, 10.2967/jnumed.110.077255
Hatt, 2010, Reproducibility of 18F-FDG and 3’-deoxy-3’-18F-fluorothymidine PET tumor volume measurements, J Nucl Med, 51, 1368, 10.2967/jnumed.110.078501
Cheebsumon, 2011, Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment, J Nucl Med, 52, 1550, 10.2967/jnumed.111.088914
Heijmen, 2012, Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer, Eur J Nucl Med Mol Imaging, 39, 1858, 10.1007/s00259-012-2233-6
Van de Wiele, 2013, Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours, Eur J Nucl Med Mol Imaging, 40, 290, 10.1007/s00259-012-2280-z
Pak, 2014, Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis, J Nucl Med, 55, 884, 10.2967/jnumed.113.133801
Ryu, 2013, Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas, J Nucl Med, 54, 1032, 10.2967/jnumed.112.116053
Lee, 2014, Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer, J Nucl Med, 55, 898, 10.2967/jnumed.113.131847
Lee, 2014, The role of metabolic tumor volume and total lesion glycolysis on (18)F-FDG PET/CT in the prognosis of epithelial ovarian cancer, Eur J Nucl Med Mol Imaging, 41, 1898, 10.1007/s00259-014-2803-x
Hatt, 2011, Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation, J Nucl Med, 52, 1690, 10.2967/jnumed.111.092767
Zaidi, 2012, Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma, Eur J Nucl Med Mol Imaging, 39, 881, 10.1007/s00259-011-2053-0
Schaefer, 2013, PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings, Eur J Nucl Med Mol Imaging, 40, 1233, 10.1007/s00259-013-2407-x
Meignan, 2014, Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells, Eur J Nucl Med Mol Imaging, 41, 1732, 10.1007/s00259-014-2815-6
Basu, 2014, FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and ßemiquantitative SUVmax” to global disease burden assessment, Eur J Nucl Med Mol Imaging, 41, 2158, 10.1007/s00259-014-2826-3
Berkowitz, 2008, Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET, Nucl Med Commun, 29, 521, 10.1097/MNM.0b013e3282f813a4
Fonti, 2012, Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma, J Nucl Med, 53, 1829, 10.2967/jnumed.112.106500
Sasanelli, 2014, Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma, Eur J Nucl Med Mol Imaging, 41, 2017, 10.1007/s00259-014-2822-7
Kanoun, 2014, Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma, Eur J Nucl Med Mol Imaging, 41, 1735, 10.1007/s00259-014-2783-x
Kim, 2013, Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma, Cancer, 119, 1195, 10.1002/cncr.27855
Visvikis, 2012, The age of reason for FDG PET image-derived indices, Eur J Nucl Med Mol Imaging, 39, 1670, 10.1007/s00259-012-2239-0
Haralick, 1973, Textural features for image classification, IEEE Trans Syst Man Cybern, SMC-3, 610, 10.1109/TSMC.1973.4309314
Brooks, 2013, On some misconceptions about tumor heterogeneity quantification, Eur J Nucl Med Mol Imaging, 40, 1292, 10.1007/s00259-013-2430-y
Cheng, 2013, The promise and limits of PET texture analysis, Ann Nucl Med, 27, 867, 10.1007/s12149-013-0759-8
Davnall, 2012, Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?, Insights Imaging, 3, 573, 10.1007/s13244-012-0196-6
Chicklore, 2013, Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis, Eur J Nucl Med Mol Imaging, 40, 133, 10.1007/s00259-012-2247-0
Galavis, 2010, Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters, Acta Oncol, 49, 1012, 10.3109/0284186X.2010.498437
Tixier, 2012, Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET, J Nucl Med, 53, 693, 10.2967/jnumed.111.099127
Hatt, 2013, Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma, Eur J Nucl Med Mol Imaging, 40, 1662, 10.1007/s00259-013-2486-8
Orlhac, 2014, Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis, J Nucl Med, 55, 414, 10.2967/jnumed.113.129858
Tixier, 2014, Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer, J Nucl Med, 55, 1235, 10.2967/jnumed.113.133389
Brooks, 2014, The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake, J Nucl Med, 55, 37, 10.2967/jnumed.112.116715
El Naqa, 2009, Exploring feature-based approaches in PET images for predicting cancer treatment outcomes, Pattern Recognit, 42, 1162, 10.1016/j.patcog.2008.08.011
Bagci, 2013, Predicting future morphological changes of lesions from radiotracer uptake in 18F-FDG-PET images, PLoS One, 8, e57105, 10.1371/journal.pone.0057105
Dong, 2013, Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor 18F-fluorodeoxyglucose uptake heterogeneity, maximum standardized uptake value, and tumor stage, Nucl Med Commun, 34, 40, 10.1097/MNM.0b013e32835ae50c
Tixier, 2011, Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer, J Nucl Med, 52, 369, 10.2967/jnumed.110.082404
Cheng, 2013, Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma, J Nucl Med, 54, 1703, 10.2967/jnumed.112.119289
Cook, 2013, Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?, J Nucl Med, 54, 19, 10.2967/jnumed.112.107375
Yang, 2013, Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer, Eur J Nucl Med Mol Imaging, 40, 716, 10.1007/s00259-012-2332-4
Bundschuh, 2014, Textural parameters of tumor heterogeneity in 18F-FDG PET/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer, J Nucl Med, 55, 891, 10.2967/jnumed.113.127340
Lambin, 2012, Radiomics: extracting more information from medical images using advanced feature analysis, Eur J Cancer, 48, 441, 10.1016/j.ejca.2011.11.036
Necib, 2011, Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging, J Nucl Med, 52, 354, 10.2967/jnumed.110.080150
David, 2012, Image change detection using paradoxical theory for patient follow-up quantitation and therapy assessment, IEEE Trans Med Imaging, 31, 1743, 10.1109/TMI.2012.2199511
Juweid, 2007, Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma, J Clin Oncol, 25, 571, 10.1200/JCO.2006.08.2305
Meignan, 2010, Report on the second international workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010, Leuk Lymphoma, 51, 2171, 10.3109/10428194.2010.529208
Meignan, 2012, Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus, Leuk Lymphoma, 53, 1876, 10.3109/10428194.2012.677535
Barrington, 2014, Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group, J Clin Oncol, 32, 3048, 10.1200/JCO.2013.53.5229
Okada, 1994, FDG-PET for predicting the prognosis of malignant lymphoma, Ann Nucl Med, 8, 187, 10.1007/BF03164996
Schöder, 2005, Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma, J Clin Oncol, 23, 4643, 10.1200/JCO.2005.12.072
Bodet-Milin, 2008, Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma, Haematologica, 93, 471, 10.3324/haematol.12013
Lin, 2007, Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis, J Nucl Med, 48, 1626, 10.2967/jnumed.107.042093
Itti, 2009, Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy, J Nucl Med, 50, 527, 10.2967/jnumed.108.057703
Casasnovas, 2011, SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma, Blood, 118, 37, 10.1182/blood-2010-12-327767
Itti, 2013, An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and SUVmax, Eur J Nucl Med Mol Imaging, 40, 1312, 10.1007/s00259-013-2435-6
Fuertes, 2013, Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma, Eur J Nucl Med Mol Imaging, 40, 496, 10.1007/s00259-012-2320-8
Rossi, 2014, Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients, J Nucl Med, 55, 569, 10.2967/jnumed.113.130609
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993, A predictive model for aggressive non-Hodgkin’s lymphoma, N Engl J Med, 329, 987, 10.1056/NEJM199309303291402
Song, 2012, Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement, Ann Hematol, 91, 697, 10.1007/s00277-011-1357-2
Song, 2012, Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma, Cancer Sci, 103, 477, 10.1111/j.1349-7006.2011.02164.x
Song, 2013, Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma, Leuk Res, 37, 58, 10.1016/j.leukres.2012.09.011
Song, 2013, Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma, Cancer Sci, 104, 1656, 10.1111/cas.12282
Meignan, 2014, Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients, Eur J Nucl Med Mol Imaging, 41, 1113, 10.1007/s00259-014-2705-y
Lowe, 1998, Prospective investigation of positron emission tomography in lung nodules, J Clin Oncol, 16, 1075, 10.1200/JCO.1998.16.3.1075
Vansteenkiste, 1998, Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients, J Clin Oncol, 16, 2142, 10.1200/JCO.1998.16.6.2142
Delbeke, 1999, Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma, J Nucl Med, 40, 1784
Boellaard, 2009, Standards for PET image acquisition and quantitative data analysis, J Nucl Med, 50, 11S, 10.2967/jnumed.108.057182
Wahl, 1993, Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation, J Clin Oncol, 11, 2101, 10.1200/JCO.1993.11.11.2101
Jansson, 1995, Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?, J Clin Oncol, 13, 1470, 10.1200/JCO.1995.13.6.1470
Findlay, 1996, Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil, J Clin Oncol, 14, 700, 10.1200/JCO.1996.14.3.700
Haberkorn, 1991, PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy, J Nucl Med, 32, 1485
Rozental, 1989, Glucose uptake by gliomas after treatment. A positron emission tomographic study, Arch Neurol, 46, 1302, 10.1001/archneur.1989.00520480044018
Minn, 1988, Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose, J Nucl Med, 29, 1521
Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4
Skougaard, 2013, Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab, J Nucl Med, 54, 1026, 10.2967/jnumed.112.111757
Engels, 2011, Phase II study of helical tomotherapy for oligometastatic colorectal cancer, Ann Oncol, 22, 362, 10.1093/annonc/mdq385
Maffione, 2013, Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy, Eur J Nucl Med Mol Imaging, 40, 853, 10.1007/s00259-013-2357-3
Fendler, 2013, Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer, J Nucl Med, 54, 1202, 10.2967/jnumed.112.116426
Tateishi, 2012, Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging – prospective assessment, Radiology, 263, 53, 10.1148/radiol.12111177
Yanagawa, 2012, Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors, J Nucl Med, 53, 872, 10.2967/jnumed.111.098699
Ziai, 2013, Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria, Cancer Imaging, 13, 73, 10.1102/1470-7330.2013.0008
Ding, 2014, PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST), J Thorac Dis, 6, 677, 10.3978/j.issn.2072-1439.2014.05.10
Tauhardt, 2014, Early detection of disease progression after palliative chemotherapy in NSCLC patients by 18F-FDG-PET, Nuklearmedizin, 53, 197, 10.3413/Nukmed-0644-14-01
Maffione, 2013, Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria, Clin Nucl Med, 38, 795, 10.1097/RLU.0b013e3182a20153
Hofman, 2010, Restaging: should we percist without pattern recognition?, J Nucl Med, 51, 1830, 10.2967/jnumed.110.079293